New ABL1 Kinase Domain Mutations in BCR::ABL1‐Positive Acute Lymphoblastic Leukemia
ABSTRACT Background Since the development of the first‐generation Tyrosine Kinase Inhibitor (TKI), it has played a crucial role in the treatment of BCR::ABL1‐positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). However, ABL1 kinase domain (ABL1 KD) mutations confer resista...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2024-10-01
|
| Серія: | Cancer Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/cam4.70317 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|